// App-Quantinova.ai

Sa1859 : Randomized Double Blind Placebo Controlled Phase II Trial of Barret-s Esophagus Chemoprevention With Metformin

Researchers

Presenter

  • Navtej Buttar

Principal Investigators

  • Nathan R. Foster

  • Anushka Baruah

  • Sonia Chowdhury

  • Sarah Kossak

  • L. M. Rodriguez

  • Ellen Richmond

  • Sumithra Mandrekar

  • Paul J. Limburg

  • Drew K. Seisler

  • Norman E. Marcon

  • Robert E. Schoen

  • Marcia R. Cruz-Correa

  • Gary W. Falk

  • Prateek Sharma

  • Chin Hur

  • Anamay N. Sharma

Medical Centers

  • Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.

  • Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN

  • University of Pittsburgh, Pittsburgh, PA

  • Massachusetts General Hospital, Boston, MA

  • Kansas City Care Ctr, Kansas City, MO

  • University Hospitals Case Medical Center, Cleveland, OH

  • Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

  • University of Pennsylvania, Philadelphia, PA

  • St. Michael's Hosp, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Obesity

  • Solid malignancies

Biomarkers

  • AMP-activated protein kinase

Drug/Treatment

  • Metformin controlled release

Outcome

  • N/A

Study Design

  • observational

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved